Cardiol Therapeutics Inc. (CRDL) Stock Analysis & Investment Frameworks
Cardiol Therapeutics Inc. (CRDL) stock analysis on Invetso. Review Cardiol Therapeutics Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Cardiol Therapeutics Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: CA
Cardiol Therapeutics Inc. Key Financial Metrics
- Market Cap: $120.06M
- Revenue: $N/A
- ROE: -180.13%
- ROIC: -148.56%
- Dividend Yield: N/A
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.